Elliot Israel, ERS 2020 – Optimising Severe Asthma Management with Biologics

We spoke with Elliot Israel (Harvard Medical School, Boston, MA, USA) about the advances being made with biologics in the treatment of type 2 asthma.

Questions

1. How have biologic therapies transformed the management of severe asthma? (0:25)
2. What have recent clinical trial data taught us about optimising the use of biologic therapies? (2:33)
3. What are the most promising emerging biologic therapies? (5:13)

Disclosures: In the last year Elliot Israel has reported personal fees from AB Science, AstraZeneca, Avillion, GlaxoSmithKline, Merck, Novartis, Pneuma Respiratory, PPS Health, Regeneron Pharmaceuticals, Sanofi Genzyme, TEVA Speciality Pharmaceuticals, ARC grants from AstraZeneca, Avillion, Gossamer Bio, Novartis and non-financial support from Circassic and TEVA Speciality Pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media.

Filmed as highlights of the ERS International Congress 2020.